expression vector pET28a(+) (Novagen), both the pET28a(+) and the pCR2.1/hLyso-PLA vectors were digested with Ndel and EcoRI, and then separated on 1% agarose gels. The bands corresponding to hLysoPLA (approx. 700 base pairs) and pET28(+) (approx. 5300 base pairs) were purified and ligated as described hereinabove. The ligation product was used to transform competent E. coli NovaBlue cells (Novagen), and the resulting colonies were screened. It should be noted that the cloned hLysoPLA has an extra 20 amino acids at the N-terminus of the protein, the sequence of which is shown in Sequence 1:

Sequence 1:

MGSSHHHHHHSSGLVPR\GSH—hLysoPLA (SEQ ID NO: 6)

His Tag thrombin site

As indicated above, the His Tag can be removed by thrombin cleavage, leaving three extra amino acids at the N-terminus of the protein.

REMARKS

The forgoing amendments are made to insert the required SEQ ID NO identifiers associated with each listed sequence provided in the above-identified patent application. No new matter is added by this amendment, whose entry is therefore requested.

Applicants believe that the present application is now in condition for allowance. Favorable reconsideration of the application as amended is respectfully requested.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application.

Respectfully submitted,

Date October 1, 2004

FOLEY & LARDNER LLP

Customer Number: 30542

Telephone:

(858) 847-6720

Facsimile:

(858) 792-6773

By

Stacy L. Taylor

Attorney for Applicant

Registration No. 34,842